BioMark Financial Statements From 2010 to 2024
| BMKDF Stock | USD 0.15 0.01 6.25% |
Check BioMark Diagnostics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BioMark Diagnostics' main balance sheet or income statement drivers, such as , as well as many indicators such as . BioMark financial statements analysis is a perfect complement when working with BioMark Diagnostics Valuation or Volatility modules.
BioMark |
BioMark Diagnostics Company Shares Outstanding Analysis
BioMark Diagnostics' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current BioMark Diagnostics Shares Outstanding | 83.29 M |
Most of BioMark Diagnostics' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BioMark Diagnostics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, BioMark Diagnostics has 83.29 M of shares currently outstending. This is 53.87% lower than that of the Healthcare sector and 41.64% lower than that of the Diagnostics & Research industry. The shares outstanding for all United States stocks is 85.43% higher than that of the company.
BioMark Diagnostics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining BioMark Diagnostics's current stock value. Our valuation model uses many indicators to compare BioMark Diagnostics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across BioMark Diagnostics competition to find correlations between indicators driving BioMark Diagnostics's intrinsic value. More Info.BioMark Diagnostics is number one stock in return on asset category among its peers. It also is number one stock in operating margin category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the BioMark Diagnostics' earnings, one of the primary drivers of an investment's value.About BioMark Diagnostics Financial Statements
BioMark Diagnostics stakeholders use historical fundamental indicators, such as BioMark Diagnostics' revenue or net income, to determine how well the company is positioned to perform in the future. Although BioMark Diagnostics investors may analyze each financial statement separately, they are all interrelated. For example, changes in BioMark Diagnostics' assets and liabilities are reflected in the revenues and expenses on BioMark Diagnostics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in BioMark Diagnostics. Please read more on our technical analysis and fundamental analysis pages.
BioMark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions to detect, monitor, and assess early treatment. BioMark Diagnostics Inc. is a subsidiary of Biomark Technologies Inc. Biomark Diagnostics operates under Diagnostics Research classification in the United States and is traded on OTC Exchange.
Currently Active Assets on Macroaxis
Other Information on Investing in BioMark Pink Sheet
BioMark Diagnostics financial ratios help investors to determine whether BioMark Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BioMark with respect to the benefits of owning BioMark Diagnostics security.